Skip to main content

Posts

Showing posts with the label type II diabetes

Determining the Effectiveness of Addition of Drug Teneligliptin to Metformin, Glimepiride, Pioglitazone Combination in Type II Diabetic Patients | Chapter 06 | New Horizons in Medicine and Medical Research Vol. 1

 Diabetes is a widespread chronic disease that has spread to epidemic proportions in almost every developed and developing country. Diabetes is the leading cause of death in the world, affecting about 400 million people. Aims and Objectives: To investigate the efficacy of combining Teneligliptin with Metformin, Glimepiride, and Pioglitazone in type 2 diabetic patients. Methodology: This was a one-year cross-sectional study on type II diabetic patients conducted in the Department of Medicine at a tertiary health care centre from January 2017 to January 2018. Out of all type II diabetes patients, 40 were randomly selected for hypoglycemic therapy with the medications Metformin, Glimepiride, and Pioglitazone. Of these, 20 were continued on the prior treatment (Group B), while the remaining 20 were given the extra drug Teneligliptin (Group A). The statistical analysis was carried out using the SPSS 19 version of software and included an unpaired t-test and a chi-square test. The ...

Determination of Diabetes and Dyslipidemia Goals in the Management of Diabetes | Chapter 6 | New Frontiers in Medicine and Medical Research Vol. 14

Diabetes Type I and Type II have an increased risk of early atherosclerotic CVD, such as CHD and PAD [1], and it is well known that glucose control improves TG levels and cholesterol-lowering has beneficial effects on CVD outcomes in T1DM and T2DM. Author (S) Details Rajesh Jain Diabetes Prevention Control Project, National Health Mission, India. Susanne Olejas World Diabetes Foundation, Denmark. Sanjeev Davey Muzaffarnagar Medical College, India. Rachna Jain Department of Obstetrics & Gynecology, Jain Hospital, India. Reza Shoghli Department of Cardiology, Azad University of Tehran, Iran. Mohammad Iqbal Consultant Diabetes in Dubai and UK. Seyed Hoseyn Ahmadi Tafti Tehran Heart Centre, Tehran, Iran. Siyamak Jalal hosseini Tehran Heart Centre, Tehran, Iran. View Book :- https://stm.bookpi.org/NFMMR-V14/article/view/3388

It is Time that Health Authorities Promote the Use of the Ozone as a Biological Modulator in the Treatment of the Chronic Oxidative Stress Diseases | Chapter 01 | Current Trends in Medicine and Medical Research Vol. 4

Ozone is a very reactive gas and is toxic for the respiratory system but, under precise rules, it can be therapeutically useful   for   human   disease   with   a   chronic   oxidative   stress.   Ozone   is   an   extremely versatile   drug   and   the   therapeutic   range   has   been   precisely   defined   to   exclude   acute   and   chronic toxicity.   It   is   remarkable   that   the   majority   of   patients   report   a   feeling   of   wellness   using   prolonged ozone therapy. Particularly in chronic skin infections and ulcers, which affect millions of patients, the use of parenteral and topical ozone applications is far more effective than conventional medications for enhancing healing, simply because ozone disinfects, oxygenates and stimulates cell proliferation. Th...